MG53 Protein-Mediated biomimetic nanotherapeutics for the treatment of acute myocardial infarction by driving the impaired plasma membrane resealing

Abstract

Myocardial infarction (MI) remains a leading global cause of mortality. The frequent disruptions of cardiomyocyte plasma membranes underscore the pivotal role played by MG53, a tissue repair protein secreted by skeletal muscle in response to physical exercise, in cardioprotection. However, the clinical application of recombinant human MG53 (rhMG53) is challenged by its short circulation half-life, necessitating frequent administration, and its low cell membrane permeability. Here we introduce an innovative MG53 protein-mediated biomimetic nanotherapeutic (Rm@mSiO2@MG53) to address the poor delivery. Rm@mSiO2@MG53 nanotherapeutics, attributed to the high specific surface area and adjustable pore size of mSiO2 and the expression of CD47 on erythrocyte membranes, enable sustained protein delivery, enhance their ability to evade the mononuclear phagocytic system (MPS), and extend the half-life of rhMG53 proteins in circulation. In a mouse MI model, Rm@mSiO2@MG53 demonstrated superior efficacy in protecting injured cardiomyocytes and preserving heart function post-MI. Our findings developed a novel protein biomimetic nanotherapeutics that mediates heart repair by driving cell membrane resealing, offering the potential to expedite the clinical deployment of rhMG53 as a viable therapeutic for treating MI and other tissue injuries.